Diabetes treatment intensification and associated changes in HbA1c and body mass index: A cohort study

BMC Endocrine Disorders

Volumn 16, Issue 1, 2016, Pages

  Roumie, Christianne L ^a,b,c   Greevy, Robert A ^a,b   Grijalva, Carlos G ^a,b   Hung, Adriana M ^a,b   Liu, Xulei ^a,b   Griffin, Marie R ^a,b  

^a GRECC   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adherence; Clinical effectiveness, treatment intensification; Clinical outcomes; Diabetes mellitus type 2; Patterns of care

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; METFORMIN; SULFONYLUREA; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; SULFONYLUREA DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; BODY MASS; COHORT ANALYSIS; COMORBIDITY; DRUG THERAPY; FEMALE; FOLLOW UP; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; TREATMENT INTENSIFICATION; DIABETES MELLITUS, TYPE 2; METABOLISM; PRACTICE GUIDELINE; TREATMENT OUTCOME;

BODY MASS INDEX; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; METFORMIN; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84971554709     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/s12902-016-0101-2     Document Type: Article

References (31)

1. Desai NR, Shrank WH, Fischer MA, Avorn J, Liberman JN, Schneeweiss S, Pakes J, Brennan TA , Choudhry NK. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications. Am J Med. 2012;125:302 e1-7.
2. Maclean JR, Chapman RH, Ferrufino CP, Krishnarajah G. Drug titration patterns and HbA 1c levels in type 2 diabetes. Int J Clin Pract. 2009;63:1008-16.
3. Huizinga MM, Roumie CL, Elasy TA, Murff HJ, Greevy R, Liu X, Speroff T, Griffin M. Changing incident diabetes regimens: a Veterans Administration cohort study from 2000 to 2005. Diabetes Care. 2007;30:e85.
4. Wysowski DK, Armstrong G, Governale L. Rapid increase in the use of oral antidiabetic drugs in the United States, 1990-2001. Diabetes Care. 2003;26:1852-5.
5. Executive summary: standards of medical care in diabetes--2009. Diabetes Care. 2009;32(Suppl 1):S6-12.
6. Standards of medical care in diabetes--2009. Diabetes Care. 2009;32(Suppl 1):S13-61.
7. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79.
8. Vijan S, Sussman JB, Yudkin JS, Hayward RA. Effect of patients' risks and preferences on health gains with plasma glucose level lowering in type 2 diabetes mellitus. JAMA Intern Med. 2014;174:1227-34.
9. Huang ES, Brown SE, Ewigman BG, Foley EC, Meltzer DO. Patient perceptions of quality of life with diabetes-related complications and treatments. Diabetes Care. 2007;30:2478-83.
10. Ismail-Beigi F, Moghissi E, Tiktin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011;154:554-9.
11. Selby JV, Uratsu CS, Fireman B, Schmittdiel JA, Peng T, Rodondi N, Karter AJ, Kerr EA. Treatment intensification and risk factor control: toward more clinically relevant quality measures. Med Care. 2009;47:395-402.
12. Kerr EA, Gerzoff RB, Krein SL, Selby JV, Piette JD, Curb JD, Herman WH, Marrero DG, Narayan KM, Safford MM, et al. Diabetes care quality in the Veterans Affairs Health Care System and commercial managed care: the TRIAD study. Ann Intern Med. 2004;141:272-81.
13. VHA/ DoD: Clinical Practice Guideline for the Management of Diabetes edition 2010. http://www.healthquality.va.gov/guidelines/CD/diabetes/. Accessed 13 Jan 2015.
14. Roumie CL, Greevy RA, Grijalva CG, Hung AM, Liu X, Murff HJ, Elasy TA, Griffin MR. Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. JAMA. 2014;311:2288-96.
15. Hung AM, Roumie CL, Greevy RA, Liu X, Grijalva CG, Murff HJ, Ikizler TA, Griffin MR. Comparative effectiveness of incident oral antidiabetic drugs on kidney function. Kidney Int. 2012;81:698-706.
16. Roumie CL, Hung AM, Greevy RA, Grijalva CG, Liu X, Murff HJ, Elasy TA, Griffin MR. Comparative effectiveness of sulfonylurea and metformin monotherapy on cardiovascular events in type 2 diabetes mellitus: a cohort study. Ann Intern Med. 2012;157:601-10.
17. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915-20.
18. Arnold N, Hines DM, Stroupe KM Comparison of VA Outpatient Prescriptions in the DSS Datasetsand the PBM Database VIREC Technical Report #1 2006. http://www.virec.research.va.gov/References/TechnicalReports/VIReCTechnicalReport1.pdf. Accessed 11 Nov 2010.
19. Centers for Medicaare and Medicaid services; ICD-9-CM: International classification of diseases, 9th revision, clinical modification. Salt Lake City, Utah: Medicode; 1988.
20. Humensky J, Carretta H, de Groot K, Brown MM, Tarlov E, Hynes D. Service Utilization of Veterans Dually Eligible for VA and Medicare Fee-For-Service: 1999-2004. 2012; 2(3). http://dx.doi.org/10.5600/mmrr.002.03.a06.
21. Hynes DM, Koelling K, Stroupe K, Arnold N, Mallin K, Sohn MW, Weaver FM, Manheim L, Kok L. Veterans' access to and use of Medicare and Veterans Affairs health care. Med Care. 2007;45:214-23.
22. Harrell F, Davis C. A new distribution-free quantile estimator. Biometrika. 1982;69:635-40.
23. Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA, Wong PK. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11:44-7.
24. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11:449-57.
25. Greevy Jr RA, Huizinga MM, Roumie CL, Grijalva CG, Murff H, Liu X, Griffin MR. Comparisons of persistence and durability among three oral antidiabetic therapies using electronic prescription-fill data: the impact of adherence requirements and stockpiling. Clin Pharmacol Ther. 2011;90:813-9.
26. Liu SC, Tu YK, Chien MN, Chien KL. Effect of antidiabetic agents added to metformin on glycaemic control, hypoglycaemia and weight change in patients with type 2 diabetes: a network meta-analysis. Diabetes Obes Metab. 2012;14:810-20.
27. Bennett WL, Maruthur NM, Singh S, Segal JB, Wilson LM, Chatterjee R, Marinopoulos SS, Puhan MA, Ranasinghe P, Block L, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2010;154:602-13.
28. American Geriatrics Society. Ten Things Physicians and Patients Should Question (Choosing Wisely campaign edition 2013). http://www.choosingwisely.org/doctor-patient-lists/american-geriatricssociety/. Accessed 18 Dec 2014.
29. Kirkman MS, Briscoe VJ, Clark N, Florez H, Haas LB, Halter JB, Huang ES, Korytkowski MT, Munshi MN, Odegard PS, et al. Diabetes in older adults. Diabetes Care. 2012;35:2650-64.
30. Pogach L, Aron D. The other side of quality improvement in diabetes for seniors: a proposal for an overtreatment glycemic measure. Arch Intern Med. 2012;172:1510-2.
31. Niesner K, Murff HJ, Griffin MR, Wasserman B, Greevy R, Grijalva CG, Roumie CL. Validation of VA administrative data algorithms for identifying cardiovascular disease hospitalization. Epidemiology. 2013;24:334-5.